FIG 2.

Association of immune checkpoint inhibitor (ICI) response with molecular alterations in ovarian cancer. (A) Somatic mutations in high-grade serous ovarian cancer (HGSOC; left) and non-HGSOC (right). Mutation types, mutational signatures, response to ICI, and BRCA1/2 status are indicated by the labels. (B) Relative percentages of patients with deleterious germline and somatic BRCA1 or BRCA2 mutations in each response group. (C) Differences in progression-free survival (PFS; left) and overall survival (OS; right) from the start of ICI as a function of presence of deleterious germline or somatic BRCA1/2 mutations. (D) Association of homologous DNA repair deficiency (HRD) status (defined by large-scale transition [LST] scores) with response in all patients (left) and the HGSOC-only cohort (right). (E) Association of tumor mutational burden (TMB) with response in all patients (left) and the HGSOC-only cohort (right). (F) Differences in PFS (left) and OS (right) from the start of ICI as a function of HRD status. (G) Differences in PFS (left) and OS (right) from the start of ICI as a function of TMB at a median cutoff. (C, F, and G) Log-rank P value is displayed. NA, not applicable; SNV, single nucleotide variant; WT, wild-type.